99.26
Kodiak Sciences Inc stock is traded at $99.26, with a volume of 1.33M.
It is down -0.61% in the last 24 hours and up +201.79% over the past month.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$99.87
Open:
$100.08
24h Volume:
1.33M
Relative Volume:
0.47
Market Cap:
$6.24B
Revenue:
Net Income/Loss:
$-230.66M
P/E Ratio:
-23.78
EPS:
-4.1742
Net Cash Flow:
$-148.12M
1W Performance:
+7.49%
1M Performance:
+201.79%
6M Performance:
+136.62%
1Y Performance:
+755.69%
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KOD
Kodiak Sciences Inc
|
99.26 | 6.24B | 0 | -230.66M | -148.12M | -4.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-26 | Resumed | Goldman | Neutral |
| May-11-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance Singapore
Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com South Africa
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Canada
Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo
A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan
Funds buy Kodiak Sciences (KOD) shares at average prices of about $79–$86. - Stock Titan
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Canada
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com South Africa
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Nigeria
Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. - Stock Titan
Diluted net income available to common stockholders of Kodiak Sciences, Inc. – HAN:K27 - TradingView
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Zacks Investment Research
Kodiak Sciences Inc (NASDAQ: KOD) Share Price, KOD Stock News, KOD Share Price & Updates - Kalkine
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com Canada
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com India
Both treatments met a year-one vision goal in Kodiak Sciences (KOD)'s eye disease trial. - Stock Titan
Why Is Kodiak Sciences (NASDAQ:KOD) Suddenly a Must-Watch Healthcare Stocks Name? - Kalkine Media
Kodiak Sciences (Nasdaq:KOD)Stock Analysis - Simply Wall Street
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha
Kodiak Sciences to report phase 3 trial results Monday By Investing.com - Investing.com South Africa
What DAYBREAK Trial Results Could Mean For Kodiak Sciences Stock - simplywall.st
Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Kodiak Sciences (KOD) Pulls Back After A Strong Year, Is The Valuation Still Too Rich? - simplywall.st
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com India
After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - marketbeat.com
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Sep 29 '26 |
Buy |
85.05 |
33,726 |
2,868,255 |
20,191,214 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
83.58 |
418,323 |
34,963,077 |
19,515,907 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
72.57 |
807,840 |
58,625,708 |
19,121,134 |
| PERLROTH VICTOR | Chairman and CEO |
Sep 25 '26 |
Option Exercise |
4.20 |
1,280,524 |
5,381,943 |
3,676,062 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
| JOHN BORGESON | Officer |
Jun 04 '26 |
Proposed Sale |
33.87 |
30,000 |
1,016,100 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Option Exercise |
1.04 |
30,000 |
31,200 |
241,930 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 15 '26 |
Option Exercise |
1.04 |
28,614 |
29,759 |
211,930 |
| JOHN BORGESON | Officer |
Apr 02 '26 |
Proposed Sale |
42.81 |
30,000 |
1,284,300 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Sale |
39.92 |
30,000 |
1,197,488 |
183,316 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):